1 **Title: Clinical features and progression of acute respiratory distress syndrome in**
2 **coronavirus disease 2019**

3
4 Yanli Liu, MD^{1,*}; Wenwu Sun, MD^{1,*}; Jia Li, PhD^{2,*}; Liangkai Chen, PhD^{3,*,#}; Yujun
5 Wang, MD¹; Lijuan Zhang, MD¹; Li Yu, MD^{1,#}.

6
7 ¹ Intensive Care Unit, the Central Hospital of Wuhan, Tongji Medical College,
8 Huazhong University of Science and Technology, Wuhan, China.

9 ² Department of Health Technology and Informatics, the Hong Kong Polytechnic
10 University, Hung Hom, Kowloon, Hong Kong PRC.

11 ³ Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food
12 Nutrition and Safety, Ministry of Education Key Lab of Environment and Health,
13 School of Public Health, Tongji Medical College, Huazhong University of Science
14 and Technology, Wuhan, China.

15
16 *** The first four authors contributed equally to this article.**

17 **# Corresponding authors:**

18 Li Yu, Email: yuliwhzxyy@163.com;

19 Liangkai Chen, Email: clk@hust.edu.cn.

20 **Word count: 2,681 (including Research in context)**

21 **No. of Tables: 3**

22 **No. of Figures: 2**

23

24 **Summary**

25 **Background:** The outbreak of severe acute respiratory syndrome coronavirus 2
26 (SARS-CoV-2) results in a cluster of coronavirus disease 2019 (COVID-19). We
27 reported the clinical characteristics of COVID-19 patients with acute respiratory
28 distress syndrome (ARDS), and further investigated the treatment and progression of
29 ARDS in COVID-19.

30 **Methods:** This study enrolled 109 patients with COVID-19 admitted to the Central
31 Hospital of Wuhan, a designated hospital in Wuhan, China, from January 2 to
32 February 1, 2020. Patients were followed up to February 12, 2020. The clinical data
33 were collected from the electronic medical records. The differences in the treatment
34 and progression with the time and the severity of ARDS were determined.

35 **Findings:** Among 109 patients, mean age was 55 years, and 59 patients were male.
36 With a median 15 days (range, 4 to 30 days) follow-up period, 31 patients (28.4%)
37 died, while 78 (71.6%) survived and discharged. Of all patients, 53 (48.6%)
38 developed ARDS. Compared to non-ARDS patients, ARDS patients were elder (mean
39 age, 61 years *vs.* 49 years), and more likely to have the coexistent conditions,
40 including diabetes (20.8% *vs.* 1.8%), cerebrovascular disease (11.3% *vs.* 0%), and
41 chronic kidney disease (15.1% *vs.* 3.6%). Compared to mild ARDS patients, those
42 with moderate and severe ARDS had higher mortality rates. No significant effect of
43 antiviral, glucocorticoid, or immunoglobulin treatment on survival was observed in
44 patients with ARDS.

45 **Interpretation:** The mortality rate increased with the severity of ARDS in COVID-19,

46 and the effects of current therapies on the survival for these patients were not

47 satisfactory, which needs more attention from clinicians.

48 **Funding:** Health and Family Planning Commission of Wuhan Municipality.

49

50 **Research in context**

51 **Evidence before this study**

52 We searched PubMed and the China National Knowledge Infrastructure database for
 53 articles published up to Feb 24, 2020, using the keywords “novel coronavirus”, “2019
 54 novel coronavirus”, “2019-nCoV”, “SARS-CoV-2”, “COVID-19”, “pneumonia”,
 55 “coronavirus”, AND “clinical feature”, “mortality”, AND “acute respiratory distress
 56 syndrome”, “ARDS”, for articles published in both Chinese and English. We found
 57 several recent articles describing the clinical characteristics of COVID-19 patients.
 58 One autopsy report described pathological findings of a 50-year-old COVID-19
 59 patient with ARDS. A recent research with 52 critically ill patients published in *The*
 60 *Lancet Respiratory Medicine* indicated that older patients concurrent ARDS are at
 61 increased risk of death. No published work about the comprehensive description of
 62 clinical features, treatment, and mortality according to the severity of ARDS in
 63 COVID-19 patients.

64 **Added value of this study**

65 We report the differences in the clinical manifestations between COVID-19 patients
 66 with and without ARDS. Among 109 patients, 53 (48.6%) of them developed ARDS.
 67 Compared with non-ARDS patients, patients with ARDS were elder and more likely
 68 to have coexistent diseases. The mortality rate in ARDS patients (49.1%) was
 69 significantly higher than that in non-ARDS patients (8.9%). The clinical
 70 characteristics of COVID-19 patients varied with the severity of ARDS. High
 71 mortality rates were found in patients with moderate and severe ARDS. The survival

72 of COVID-19 patients with ARDS was not significantly improved by the antiviral,
73 glucocorticoid, or immunoglobulin treatment.

74 **Implications of all the available evidence**

75 In the front-line epidemic area, COVID-19 patients with moderate-to-severe ARDS
76 had high mortality rates. The current medical treatments might not have a satisfactory
77 effect on the in-hospital survival of COVID-19 patients with ARDS. For clinicians, it
78 is necessary to pay close attention to COVID-19 patients who are at high risk for
79 ARDS. The risk stratification and therapeutic strategy for COVID-19 patients should
80 be tailored according the variations in ARDS severity. It is essential for intensive care
81 physicians to participate in treatment decision-making and management in the early
82 stages of the COVID-19 outbreak.

83

84 Introduction

85 The emergent outbreaks of coronavirus disease 2019 (COVID-19) caused by the
86 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain a threat
87 to the public health worldwide ^{1,2}. As of February 24, 2020, 77,262 cases were
88 confirmed, and 2,595 death cases were recorded in China. The number of confirmed
89 cases in other countries are ascending as well ³⁻⁵. COVID-19 may impose a great
90 socioeconomic, public health, and clinical burden, especially in the low-income and
91 middle-income countries.

92

93 Growing studies identified the clinical features of COVID-19 ⁶⁻⁸. Similar to SARS in
94 2003, this infectious disease results in the high possibility of the admission to the
95 intensive care unit (ICU) and the mortality ⁶. Notably, due to the cytokine cascade
96 within a short period, the critically ill patients with COVID-19 were more likely to
97 develop acute respiratory distress syndrome (ARDS) and receive oxygen treatment ⁶.
98 ARDS was the most common complication in COVID-19 patients, with a high
99 mortality rate ^{6,7}. The latest publication in *The Lancet Respiratory Medicine*, Yang *et*
100 *al.* ⁹ reported that 67% of critically ill patients develop ARDS. However, little is
101 known regarding the clinical characteristics, treatment, and progression of COVID-19
102 patients according to the severity of ARDS.

103

104 In this study, we retrospectively reviewed the clinical data of patients with COVID-19
105 who were admitted to the Central Hospital of Wuhan, and determined the differences

106 in the clinical characteristics between COVID-19 patients with and without ARDS.
107 Additionally, to reveal the evolvement of ARDS in COVID-19, we also investigated
108 the clinical features and therapies of COVID-19 patients at each severity level of
109 ARDS. Our study might provide new insight into the risk stratification and
110 therapeutic strategy for COVID-19 patients.

111

112 **Methods**

113 **Study Population**

114 We retrospectively analyzed the data of confirmed COVID-19 patients admitted to the
115 Central Hospital of Wuhan between January 2 and February 1, 2020. The Central
116 Hospital of Wuhan is one of the first designated hospitals to receive patients with
117 COVID-19. According to the World Health Organization interim guidance¹⁰, the
118 diagnostic criteria of COVID-19 was based on the virus RNA detection, the clinical
119 characteristics, the chest imaging, and the ruling out common pathogen. Patients with
120 malignant tumors, previous craniocerebral operation, or died on admission were
121 excluded. In this study, we also excluded patients who had been transferred to other
122 hospitals for advanced life support and patients with mild symptoms who had been
123 transferred to mobile cabin hospitals. The clinical outcomes of patients were followed
124 up to February 12, 2020. Patients who were still in hospital before February 12, 2020
125 were excluded. Finally, 109 confirmed COVID-19 patients were included in the
126 analyses. All data were anonymous, and the requirement for informed consent was
127 waived. The Ethics Committees of the Central Hospital of Wuhan approved this study.

128

129 **Data Collection**

130 Case report forms, nursing records, laboratory findings, and radiological features were
131 reviewed. All data were collected onto the standardized forms from the electronic
132 medical records in the hospital. Two senior physicians independently reviewed the
133 data. Information on demographic data, symptoms, underlying comorbidities, chest
134 computed tomographic images, and laboratory results were included. All treatment
135 measures were collected during the hospitalization, such as antiviral therapy,
136 antibacterial therapy, corticosteroid therapy, immune support therapy, and respiratory
137 support. The time of disease onset was defined as the day of symptom onset. The time
138 from the first symptom to the fever clinics, hospital admission, and clinical outcomes
139 were recorded. A confirmed respiratory tract specimen was defined as positive for
140 SARS-CoV-2. Repeated tests for SARS-CoV-2 were done in the confirmed patients to
141 show viral clearance before the hospital discharge. The Berlin definition was applied
142 to determine the presence and severity of ARDS ¹¹. Acute Physiology and Chronic
143 Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA)
144 scores and CURB-65 criteria ¹² were determined within 24 hours after admission.

145

146 **Detection of Coronavirus by Real-Time Reverse Transcription Polymerase Chain** 147 **Reaction**

148 Throat swab samples were collected from the suspected patients, and the method of
149 virus RNA detection was reported ⁷. Briefly, the presence of SARS-CoV-2 in the

150 respiratory specimens was detected by real-time reverse transcription polymerase
151 chain reaction (RT-PCR). Two target genes were used, including open reading frame
152 lab (ORF1ab) and nucleocapsid protein (N), and the sequences were as follows:
153 ORF1ab: forward primer CCCTGTGGGTTTTACTTAA; reverse primer
154 ACGATTGTGCATCAGCTGA. N: forward primer
155 GGGGAAGTTCTCCTGCTAGAAT; reverse primer
156 CAGACATTTTGCTCTCAAGCTG. The real-time RT-PCR assay was conducted in
157 line with the manufacturer's protocol (Beijing Genomics Institution and Geneodx
158 biotechnology Co. Ltd). Positive test results for two target genes were considered as
159 laboratory-confirmed infection.

160

161 **Statistical Analysis**

162 Normally distributed continuous variables were presented as mean $\pm$ SD, compared
163 by Student's t-test. Skew distributed continuous variables were shown as median
164 (interquartile range [IQR]), analyzed by Mann–Whitney test or Kruskal–Wallis test.
165 Categorical variables were compared by Chi-square test or the Fisher's exact test.
166 Kaplan–Meier methods were used for survival plotting, and log-rank test for
167 comparison of survival curves. The dynamic trajectory in laboratory parameters was
168 plotted using GraphPad Prism 8 (GraphPad Software, Inc). Generalized linear mixed
169 models examined the differences in the laboratory data between ARDS and non-
170 ARDS groups over time. All statistical analysis were performed by the statistical
171 software packages R (<http://www.R-project.org>, The R Foundation) and the

172 EmpowerStats (<http://www.empowerstats.com>, X&Y Solutions, Inc., Boston, MA)

173 with a two-sided significance threshold of $P < 0.05$.

174

175 **Results**

176 **Clinical Characteristics**

177 A total of 109 patients with COVID-19 were included in the current study. The
178 baseline clinical parameters of overall COVID-19 patients and COVID-19 patients
179 with and without ARDS were summarized in **Table 1**. Mean age of all subjects was
180 55 years (IQR, 43-66 years; range, 22-94 years), and 54.1% of all patients were male.
181 The most common symptom at the illness onset was fever (82.6%), followed by dry
182 cough (61.5%) and fatigue (56.9%). Seventy-six patients (69.7%) had underlying
183 comorbidities, including hypertension (33.9%), diabetes (11.0%), and chronic kidney
184 disease (9.2%). The first virus RNA detection rate was 24.8% in the fever clinics, and
185 all patients were reconfirmed by repeated virus RNA testing after admission. Among
186 109 patients, 53 (48.6%) of them developed ARDS, 100 (91.7%) of them had bilateral
187 involvement of the chest radiographs, and 28 (25.7%) patients received high-flow
188 nasal oxygen ventilation, while 31 (28.4%) died.

189

190 Compared with non-ARDS patients with COVID-19, ARDS patients were elder
191 (mean age, 61 years *vs.* 49 years), and more likely to have coexistent diabetes (20.8%
192 *vs.* 1.8%), cerebrovascular disease (11.3% *vs.* 0%), and chronic kidney disease (15.1%
193 *vs.* 3.6%). The bilateral involvement in the chest radiographs was identified in all

194 ARDS patients, but in 83.9% non-ARDS patients. The likelihood to receive high-flow
195 nasal ventilation for ARDS patients (49.1%) was significantly higher than that for
196 non-ARDS patients (3.6%). The mortality rate in ARDS patients (49.1%) was also
197 significantly higher than that in non-ARDS patients (8.9%).

198

199 **Disease Severity Scores and Laboratory Findings in COVID-19 Patients With** 200 **and Without ARDS**

201 The disease severity evaluation and laboratory examination of non-ARDS and ARDS
202 patients with COVID-19 on admission were shown in **Table 2**. Compared with non-
203 ARDS subjects, ARDS subjects had significantly higher disease severity on the day of
204 hospital admission (all *P* values <0.001 for CURB-65, SOFA, and APACHE II).
205 ARDS patients were more likely accompanied by lymphopenia on admission (*P* value
206 <0.001). Besides, the levels of lactate, neutrophil count, C-reactive protein (CRP), and
207 procalcitonin were significantly higher in ARDS patients than in non-ARDS patients
208 (median lactate level, 1.6 vs. 1.1 mmol/L; median neutrophil count level, 4.1 vs. 3.2
209 $\times 10^9/L$; median CRP level, 4.9 vs. 2.0 mg/dL; median procalcitonin level, 0.15 vs.
210 0.06 ng/mL). Significant increased levels of blood urea nitrogen, serum fibrinogen, D-
211 dimer, and lactate dehydrogenase in ARDS patients were observed, compared with
212 those in non-ARDS patients (all *P* values <0.05).

213

214 As shown in **Figure 1**, the dynamic trajectory in nine laboratory parameters were
215 tracked on Day 1, 3, 7 and 14, respectively. Significant differences in the levels of

neutrophil count, lymphocyte count, CRP, procalcitonin, and D-dimer were found between ARDS and non-ARDS patients with COVID-19 (all P values <0.05). From Day 1 to 14, ARDS patients had significantly lower lymphocyte count levels, while the levels of other laboratory findings were higher in ARDS patients.

Clinical Profile and Progression of COVID-19 Patients With ARDS

According to the severity of ARDS, we further analyzed the clinical features, treatment, and progression of 53 COVID-19 patients with ARDS. As presented in **Table 3**, the increase in APACHE II, SOFA, and CURB criteria scores occurred concomitantly with the severity of ARDS (all P values <0.001). The levels of lactate, blood urea nitrogen, D-dimer, and lactate dehydrogenase ascended with the severity of ARDS (all P values <0.05), whereas the lymphocyte count levels decreased (P value = 0.045). Patients with moderate-to-severe ARDS were the most likely to receive glucocorticoid therapy (P value = 0.02) and high-flow nasal oxygen ventilation (P value <0.001). Compared to patients with mild ARDS, those with moderate and severe ARDS had higher mortality rates (P value <0.001). Subsequent survival analysis was shown in **Figure 2**. We found no significant effect of antiviral, glucocorticoid, or immunoglobulin treatment on survival in COVID-19 patients with ARDS (all log-rank tests $P >0.05$).

Discussion

237 In the present study of ARDS progression in COVID-19, we firstly identified the
238 differences in the clinical manifestations between COVID-19 patients with and
239 without ARDS. Second, the clinical characteristics of COVID-19 patients varied with
240 the severity of ARDS. High mortality rates were observed in patients with moderate-
241 to-severe ARDS. Third, we did not observe any apparent effect of the current
242 therapeutic interventions on the in-hospital survival of COVID-19 patients with
243 ARDS. Our findings might highlight the clinical significance in the enhanced
244 attention towards COVID-19 patients at high risks of ARDS.

245

246 To the best of our knowledge, this study is the first to investigate the clinical features
247 and progression of SARS-CoV-2 infected patients according to the severity of ARDS.
248 We revealed that elder patients, or complicated by diabetes, cerebrovascular disease,
249 and chronic kidney disease, were more likely to develop ARDS. This finding might
250 further explain the significant association of age and comorbidity conditions with the
251 poor clinical outcomes in a previous COVID-19 study⁷. In addition, the elevated
252 levels of neutrophil count, CRP, procalcitonin and D-dimer, but the decreased
253 lymphocyte count levels, were detected in patients with ARDS, rather than those
254 without ARDS. Similarly, the levels of lactate and D-dimer increased with the
255 progression of ARDS due to SARS-CoV-2, while severer lymphopenia occurred over
256 time. Our investigations into these laboratory indicators were comparable with other
257 COVID-19 studies^{6,7,13}, suggesting that cytokine cascade, excessive inflammatory

258 reaction, and coagulation dysfunction might evolve in the course of ARDS resulted
259 from SARS-CoV-2.

260

261 Our understanding of this ARDS progression could be furthered by a recent autopsy
262 report on a 50-year-old COVID-19 patient with ARDS ¹⁴, which was highlighted by
263 the inflammatory infiltration of lymphocytes in both lungs and the immune
264 hyperactivation in the patient. Interestingly, no obvious heart injury occurred in this
265 patient, while the liver injury might be caused by SARS-CoV-2 infection or
266 medication use ¹⁴. These pathological results were concordant with our clinical
267 observation of a dysregulated inflammatory and immune state in COVID-19 patients
268 with ARDS, which might in turn help to guide our medical therapy.

269

270 The medical management of ARDS has advanced remarkably during the past decades
271 ¹⁵. However, the general mortality rates of ARDS caused by all etiologies fluctuated
272 from 11% to 87% ¹⁶. In our study, most patients with COVID-19 received antibiotics
273 and antiviral treatment, while over half of them were given by glucocorticoid and
274 intravenous immunoglobulin therapies. Moderate-to-severe ARDS patients were more
275 likely to use high-flow nasal oxygen ventilation. Unfortunately, the mortality rate was
276 extremely high in severe ARDS patients with COVID-19, and the survival of COVID-
277 19 patients with ARDS was not improved by the antiviral, glucocorticoid, or
278 immunoglobulin treatment. Some potential reasons might interpret the high mortality
279 we observed: First, due to the SARS-CoV-2 outbreak within a short period, the

280 designated hospitals were overloaded in short term, with inadequate medical facilities
281 and insufficient medical staff. Notably, intensive care resources are in short supply
282 and may fail to meet demand under the increasing number critically ill patients.

283 Second, the Central Hospital of Wuhan is close to Huanan Seafood Market, and the
284 inpatients were the first or the second generation infected patients. In addition, the
285 inadequate preparation and insufficient understanding of the disease might contribute
286 to increased mortality in the front-line epidemic area during the early outbreak period.

287
288 The epidemic spread knows no borders. We are deeply concerned about the current
289 outbreak of SARS-CoV-2. As the low-income and middle-income countries are more
290 vulnerable to the lack of medical resources, the mortality rate of infectious diseases
291 may be even higher. Therefore, from a policy perspective, the government should
292 provide capital, technology, and manpower to curb the epidemic. Meanwhile, in the
293 front-line epidemic area, limited medical resources should be allocated reasonably
294 and effectively. Based on our observation, some patients progress quickly to severe
295 pneumonia or ARDS without warning sign. Adequate critical care resources and the
296 involvement of intensive care physicians are essential in the early stages of the SARS-
297 CoV-2 outbreak.

298
299 The present study is subjected to several limitations. Due to the retrospective nature of
300 the present study, a systematic selection bias could be introduced. We could not
301 completely address the residual confounding factors as well. Although our laboratory

302 observations showed the significant changes with the time and the severity of ARDS,
303 the clinical predictive value remained to be determined. In addition, our results on the
304 effect of the current treatments should be considered with caution, and high-quality
305 clinical interventional studies are needed. Meanwhile, the benefits of the invasive
306 ventilation therapy on the disease prognosis should be further investigated. In the
307 future, a multi-center and follow-up study with a larger cohort is eagerly warranted.

308

309 **Conclusions**

310 In the current study from one of the designated hospitals in Wuhan, China, the
311 significant changes with the time and the severity of ARDS were observed in COVID-
312 19 patients. Moreover, COVID-19 patients with moderate and severe ARDS had high
313 mortality rates. The current medical treatments might not have a significant effect on
314 the in-hospital survival of COVID-19 patients with ARDS. Our observations might
315 help to guide the risk stratification and therapeutic strategy for COVID-19 patients.

316

317 **Acknowledgement**

318 We deeply regret and mourn all the lives lost in this disaster of SARS-CoV-2,
319 including our dearest colleague Dr. Wenliang Li. We would like to express our deepest
320 respect to all the people who are currently fighting against the outbreak of COVID-19.

321

322 **Authors Contributions**

323 LC and YL had full access to all the data in the study, and took responsibility for the
324 integrity of the data and the accuracy of the data analysis. YL, WS, LC, and LY made
325 substantial contributions to the study concept and design. YL and WS took
326 responsibility for obtaining ethical approval, collecting samples, and confirming data
327 accuracy. LC was in charge of the statistical analysis. YL, JL, and LC were in charge
328 of the manuscript draft. JL, LC, LZ, YW, and LY contributed to critical revision of the
329 report. All authors reviewed and approved the final version.

330

331 **Conflict of Interest Disclosures**

332 The authors declared no conflict of interest.

333

334 **Role of the funding source**

335 This study was supported by the Health and Family Planning Commission of Wuhan
336 Municipality, grant number WX18A02. The funders had no role in the design and
337 conduct of the study; collection, management, analysis, and interpretation of the data;

338 preparation, review, or approval of the manuscript; and decision to submit the

339 manuscript for publication.

340

341 **Data sharing**

342 The data that support the findings of this study are available from the corresponding

343 authors on reasonable request. We can provide participant data without names and

344 identifiers, but not the study protocol, or statistical analysis plan. After publication of

345 study findings, the data will be available for others to request. Once the data can be

346 made public, the research team will provide an email address for communication. The

347 corresponding authors have the right to decide whether to share the data or not based

348 on the research objectives and plan provided.

349

350 References

- 351 1. Hui DS, E IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel
352 coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J*
353 *Infect Dis* 2020; **91**: 264-6.
- 354 2. Velavan TP, Meyer CG. The COVID-19 epidemic. *Trop Med Int Health* 2020.
- 355 3. Team C-NIRS. COVID-19, Australia: Epidemiology Report 3 (Reporting week ending 19:00
356 AEDT 15 February 2020). *Commun Dis Intell (2018)* 2020; **44**.
- 357 4. Smith N, Fraser M. Straining the System: Novel Coronavirus (COVID-19) and Preparedness
358 for Concomitant Disasters. *Am J Public Health* 2020: e1-e2.
- 359 5. Habibzadeh P, Stoneman EK. The Novel Coronavirus: A Bird's Eye View. *Int J Occup Environ*
360 *Med* 2020; **11**(2): 65-71.
- 361 6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
362 coronavirus in Wuhan, China. *Lancet* 2020; **395**(10223): 497-506.
- 363 7. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019
364 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.
- 365 8. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
366 Coronavirus-Infected Pneumonia. *N Engl J Med* 2020.
- 367 9. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-
368 CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet*
369 *Respiratory Medicine*.
- 370 10. World Health Organization. Clinical management of severe acute respiratory infection when
371 novel coronavirus (nCoV) infection is suspected: interim guidance. [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_2)
372 [source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_2](https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_2). Published January 28,
373 2020. Accessed February 12, 2020.
- 374 11. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin
375 Definition. *JAMA* 2012; **307**(23): 2526-33.
- 376 12. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia
377 severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003;
378 **58**(5): 377-82.
- 379 13. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019
380 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;
381 **395**(10223): 514-23.
- 382 14. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute
383 respiratory distress syndrome. *The Lancet Respiratory Medicine*.
- 384 15. Peck TJ, Hibbert KA. Recent advances in the understanding and management of ARDS.
385 *F1000Res* 2019; **8**.
- 386 16. Maca J, Jor O, Holub M, et al. Past and Present ARDS Mortality Rates: A Systematic Review.
387 *Respir Care* 2017; **62**(1): 113-22.

388

389 **Table 1. Baseline clinical features of subjects with COVID-19.**

	No. (%)			P-value ^a
	Total (n = 109)	Non-ARDS (n = 56)	ARDS (n = 53)	
Age, median (IQR), y	55 (43-66)	49 (37-59)	61 (52-70)	<0.001
Male	59 (54.1)	31 (55.4)	28 (52.8)	0.79
Entering complaint				
Fever	90 (82.6)	48 (85.7)	42 (79.2)	0.37
Dry cough	67 (61.5)	36 (64.3)	31 (58.5)	0.53
Fatigue	62 (56.9)	26 (46.4)	36 (67.9)	0.02
Stethalgia	7 (6.4)	4 (7.1)	3 (5.7)	0.75
Diarrhea	12 (11.0)	6 (10.7)	6 (11.3)	0.92
Comorbidities				
COPD	4 (3.7)	2 (3.6)	2 (3.8)	>0.99
Hypertension	37 (33.9)	16 (28.6)	21 (39.6)	0.22
Diabetes	12 (11.0)	1 (1.8)	11 (20.8)	0.002
Cardiovascular disease	7 (6.4)	4 (7.1)	3 (5.7)	>0.99
Cerebrovascular disease	6 (5.5)	0 (0.0)	6 (11.3)	0.01
Chronic kidney disease	10 (9.2)	2 (3.6)	8 (15.1)	0.049
Onset of symptom to fever clinics, median (IQR), d	4 (2-6)	4 (2-7)	4 (2-6)	0.88
Onset of symptom to hospital admission, median (IQR), d	7 (5-9)	7 (5-9)	7 (5-9)	0.58
Hospital stays, median (IQR), d	15 (11-24)	15 (9-27)	16 (11-23)	0.41
Nucleic acid test (+) in fever clinics	27 (24.8)	12 (21.4)	15 (28.3)	0.41
Bilateral involvement of chest radiographs	100 (91.7)	47 (83.9)	53 (100)	0.002
Fever clinics treatment				
Antibiotics	105 (96.3)	55 (98.2)	50 (94.3)	0.35

Antivirus	105 (96.3)	55 (98.2)	50 (94.3)	0.35
Glucocorticoid therapy	43 (39.4)	20 (35.7)	23 (43.4)	0.41
Intravenous immunoglobulin	32 (29.4)	19 (33.9)	13 (24.5)	0.28
In-patient treatment				
Antibiotics	106 (97.2)	53 (94.6)	53 (100.0)	0.24
Antivirus	107 (98.2)	55 (98.2)	52 (98.1)	>0.99
Glucocorticoid therapy	72 (66.1)	35 (62.5)	37 (69.8)	0.42
Intravenous immunoglobulin	61 (56.0)	32 (57.1)	29 (54.7)	0.80
High-flow nasal ventilation	28 (25.7)	2 (3.6)	26 (49.1)	<0.001
Death	31 (28.4)	5 (8.9)	26 (49.1)	<0.001

Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; IQR, interquartile range;

^a *p* values indicate differences between non-ARDS and ARDS patients.

390
391
392

393 **Table 2. Severity of COVID-19 and laboratory tests in Non-ARDS and ARDS subjects.**

	Normal range	Median (IQR)			P-value ^a
		Total (n = 109)	Non-ARDS (n = 56)	ARDS (n = 53)	
Severity of illness scores and blood gas analysis on admission to hospital					
CURB-65	NA	0 (0-1)	0 (0-1)	1 (0-2)	<0.001
SOFA	NA	2 (1-4)	1 (0-1)	4 (2-5)	<0.001
APACHE II	NA	4 (2-8)	2 (1-3)	8 (5-10)	<0.001
Lactate, mmol/L	0.5-1.6	1.3 (0.8-2.0)	1.1 (0.8-1.6)	1.6 (1.1-2.2)	<0.001
PaO ₂ :FiO ₂ , mm Hg	400-500	296 (142-435)	475 (398-524)	145 (108-250)	<0.001
Laboratory findings on admission to hospital					
White blood cell count, ×10 ⁹ /L	3.5-9.5	5.2 (4.0-7.0)	4.9 (3.8-6.2)	5.4 (4.5-8.0)	0.053
Neutrophil count, ×10 ⁹ /L	1.8-6.3	3.6 (2.8-5.6)	3.2 (2.4-4.2)	4.1 (3.1-7.1)	0.004
Lymphocyte count, ×10 ⁹ /L	1.1-3.2	0.9 (0.5-1.2)	1.0 (0.8-1.4)	0.7 (0.4-1.1)	<0.001
C-reactive protein, mg/dL	0-0.5	3.1 (1.1-5.4)	2.0 (0.9-3.2)	4.9 (2.7-6.5)	<0.001
Procalcitonin, ng/mL	<0.05	0.09 (0.06-0.20)	0.06 (0.05-0.09)	0.15 (0.08-0.37)	<0.001
Blood urea nitrogen, mmol/L	2.8-8	4.3 (3.3-6.5)	3.5 (2.9-4.8)	5.5 (4.0-7.1)	<0.001
Creatinine, μmol/L	57-111	65 (55-82)	64 (52-80)	67 (55-83)	0.42
Total bilirubin, mmol/L	0-21	9.0 (6.5-13.4)	8.3 (6.8-11.7)	10.5 (6.2-14.8)	0.23
Alanine aminotransferase, U/L	9-50	23 (15-36)	23 (14-41)	24 (16-31)	0.82
Aspartate aminotransferase, U/L	15-40	30 (21-40)	29 (19-38)	31 (25-44)	0.17
Fibrinogen, g/L	2-4	3.1 (2.7-3.6)	2.9 (2.7-3.3)	3.4 (2.9-3.9)	0.001
D-dimer, mg/L	0-500	570 (300-1178)	370 (250-650)	940 (470-1905)	<0.001
Lactate dehydrogenase, U/L	135-225	238 (185-341)	209 (183-267)	264 (190-448)	0.011
Creatine kinase, U/L	<190	91 (52-178)	100 (53-183)	83 (49-169)	0.29

Creatine kinase–MB, U/L	<25	9.0 (6.1-14.8)	8.5 (6.0-12.5)	10.4 (7.0-15.1)	0.28
-------------------------	-----	----------------	----------------	-----------------	------

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; FiO₂, fraction of inspired oxygen; IQR, interquartile range; NA, not available; PaO₂, partial pressure of oxygen; SOFA, Sequential Organ Failure Assessment

^a *p* values indicate differences between non-ARDS and ARDS patients.

398 **Table 3. Clinical characteristics, laboratory findings, and treatment according to the severity of ARDS.**

	Normal range	Median (IQR)			P-value ^a
		Mild ARDS (n = 19)	Moderate ARDS (n = 24)	Severe ARDS (n = 10)	
Age, y	NA	52 (46-63)	65 (57-70)	67 (55-71)	0.04
Severity of illness scores and blood gas analysis on admission to hospital					
CURB-65	NA	0 (0-1)	1 (1-2)	2 (1-3)	<0.001
SOFA	NA	2 (2-3)	4 (3-5)	6 (5-6)	<0.001
APACHE II	NA	3 (2-6)	8 (7-12)	10 (8-13)	<0.001
Lactate, mmol/L	0.5-1.6	1.2 (0.8-1.7)	1.8 (1.1-2.3)	5.2 (2.0-10.0)	<0.001
PaO ₂ :FiO ₂ , mm Hg	400-500	276 (247-280)	140 (117-153)	85 (57-88)	<0.001
Laboratory findings on admission to hospital					
White blood cell count, ×10 ⁹ /L	3.5-9.5	4.6 (3.8-5.0)	7.3 (5.2-10.5)	7.0 (4.6-8.0)	0.006
Neutrophil count, ×10 ⁹ /L	1.8-6.3	3.2 (2.3-3.8)	6.0 (4.2-9.0)	5.3 (3.7-7.3)	0.002
Lymphocyte count, ×10 ⁹ /L	1.1-3.2	0.9 (0.7-1.3)	0.6 (0.4-0.9)	0.5 (0.4-0.8)	0.045
C-reactive protein, mg/dL	0-0.5	4.1 (2.2-5.9)	4.1 (1.9-9.7)	6.7 (5.5-12.2)	0.027
Procalcitonin, ng/mL	<0.05	0.10 (0.08-0.21)	0.16 (0.08-0.55)	0.28 (0.22-1.52)	0.09
Blood urea nitrogen, mmol/L	2.8-8	4.5 (3.5-6.1)	5.6 (4.5-7.7)	7.1 (6.0-8.0)	0.03
Creatinine, μmol/L	57-111	67 (58-74)	65 (54-99)	70 (55-80)	0.89
Total bilirubin, mmol/L	0-21	7.9 (5.8-10.4)	13.2 (9.3-18.6)	13.2 (6.2-13.5)	0.07
Alanine aminotransferase, U/L	9-50	24 (15-34)	24 (21-27)	21 (15-32)	0.90
Aspartate aminotransferase, U/L	15-40	29 (21-43)	34 (27-44)	29 (27-36)	0.45
Fibrinogen, g/L	2-4	3.3 (2.8-3.6)	3.4 (2.9-4.3)	3.6 (3.4-4.1)	0.41
D-dimer, mg/L	0-500	330 (220-798)	1220 (695-4035)	1385 (985-7550)	<0.001

Lactate dehydrogenase, U/L	135-225	190 (166-238)	347 (255-504)	458 (286-549)	0.001
Creatine kinase, U/L	<190	69 (44-119)	92 (58-185)	66 (53-188)	0.49
Creatine kinase–MB, U/L	<25	8.0 (6.5-11.6)	11.1 (6.8-16.1)	10.9 (8.9-12.0)	0.37
In-patient treatment, <i>n</i> (%)					
Ribavirin	NA	18 (94.7)	18 (75.0)	10 (100.0)	0.08
Oseltamivir	NA	5 (26.3)	8 (33.3)	1 (10.0)	0.43
Arbidol	NA	3 (15.8)	2 (8.3)	1 (10.0)	0.85
Glucocorticoid therapy	NA	9 (47.4)	21 (87.5)	7 (70.0)	0.02
Intravenous immunoglobulin	NA	13 (68.4)	9 (37.5)	7 (70.0)	0.08
High-flow nasal ventilation, <i>n</i> (%)	NA	1 (5.3)	19 (79.2)	6 (60.0)	<0.001
Hospital stays, d	NA	18 (13-25)	18 (15-25)	11 (10-13)	0.03
Death, <i>n</i> (%)	NA	1 (5.3)	15 (62.5)	10 (100.0)	<0.001

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; FiO₂, fraction of inspired oxygen; IQR, interquartile range; NA, not available; PaO₂, partial pressure of oxygen; SOFA, Sequential Organ Failure Assessment

^a *p* values indicate differences among mild, moderate, and severe ARDS patients.

Figure legends

Figure 1. Timeline charts illustrate the laboratory parameters in 109 patients with COVID-19 (56 non-ARDS and 53 ARDS) on day 1, day 3, day 7, and day 14 after admission. Data are represented as geometric mean and 95% confidence interval (one group only shows the upper or lower bar). The dash lines in black show the upper normal limit of each parameter, and the dash line in red shows the lower normal limit of lymphocyte count.

* $P < 0.05$ for non-ARDS vs. ARDS.

Figure 2. Kaplan-Meier survival curves for 53 COVID-19 patients concurrent ARDS. (A) Ribavirin; (B) Oseltamivir; (C) Arbidol; (D) Glucocorticoid therapy; (E) Intravenous immunoglobulin.